1207 related articles for article (PubMed ID: 24444771)
21. Do the therapeutic effects of psilocybin involve actions in the gut?
Reed F; Foldi CJ
Trends Pharmacol Sci; 2024 Feb; 45(2):107-117. PubMed ID: 38216431
[TBL] [Abstract][Full Text] [Related]
22. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.
Carhart-Harris RL; Leech R; Erritzoe D; Williams TM; Stone JM; Evans J; Sharp DJ; Feilding A; Wise RG; Nutt DJ
Schizophr Bull; 2013 Nov; 39(6):1343-51. PubMed ID: 23044373
[TBL] [Abstract][Full Text] [Related]
23. Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
Ehrmann K; Allen JJB; Moreno FA
Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024
[TBL] [Abstract][Full Text] [Related]
24. The promises and perils of psychedelic pharmacology for psychiatry.
McClure-Begley TD; Roth BL
Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
[TBL] [Abstract][Full Text] [Related]
25. Psilocybin: Good Trip or Bad Trip.
Sellers EM
Clin Pharmacol Ther; 2017 Oct; 102(4):580-584. PubMed ID: 28548221
[TBL] [Abstract][Full Text] [Related]
26. Psychedelics as Medicines: An Emerging New Paradigm.
Nichols DE; Johnson MW; Nichols CD
Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026
[TBL] [Abstract][Full Text] [Related]
27. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.
Hesselgrave N; Troppoli TA; Wulff AB; Cole AB; Thompson SM
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33850049
[TBL] [Abstract][Full Text] [Related]
28. The zebrafish for preclinical psilocybin research.
Syed OA; Tsang B; Gerlai R
Neurosci Biobehav Rev; 2023 Oct; 153():105381. PubMed ID: 37689090
[TBL] [Abstract][Full Text] [Related]
29. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.
Dinis-Oliveira RJ
Drug Metab Rev; 2017 Feb; 49(1):84-91. PubMed ID: 28074670
[TBL] [Abstract][Full Text] [Related]
30. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
Bogenschutz MP; Forcehimes AA; Pommy JA; Wilcox CE; Barbosa PC; Strassman RJ
J Psychopharmacol; 2015 Mar; 29(3):289-99. PubMed ID: 25586396
[TBL] [Abstract][Full Text] [Related]
31. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Applications of Classic Hallucinogens.
Bogenschutz MP; Ross S
Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
[TBL] [Abstract][Full Text] [Related]
33. Effects of psilocybin on time perception and temporal control of behaviour in humans.
Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
[TBL] [Abstract][Full Text] [Related]
34. [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
Jastrzebski M; Bala A
Psychiatr Pol; 2013; 47(6):1157-67. PubMed ID: 25007546
[TBL] [Abstract][Full Text] [Related]
35. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
Carter OL; Hasler F; Pettigrew JD; Wallis GM; Liu GB; Vollenweider FX
Psychopharmacology (Berl); 2007 Dec; 195(3):415-24. PubMed ID: 17874073
[TBL] [Abstract][Full Text] [Related]
36. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR
J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767
[TBL] [Abstract][Full Text] [Related]
37. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
Studerus E; Kometer M; Hasler F; Vollenweider FX
J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
[TBL] [Abstract][Full Text] [Related]
38. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
[TBL] [Abstract][Full Text] [Related]
39. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
[TBL] [Abstract][Full Text] [Related]
40. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
Wulff AB; Nichols CD; Thompson SM
Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
